Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma
1996

Efficacy and Safety of Stealth Liposomal Doxorubicin in AIDS-Related Kaposi's Sarcoma

Sample size: 247 publication Evidence: moderate

Author Information

Author(s): F-D Goebel, D Goldstein, M Goos, H Jablonowski, JS Stewart

Hypothesis

The study aims to evaluate the efficacy and safety of Stealth liposomal doxorubicin (SL-DOX) in treating moderate to severe AIDS-related Kaposi's sarcoma.

Conclusion

SL-DOX shows substantial activity in treating AIDS-related Kaposi's sarcoma with manageable toxicity.

Supporting Evidence

  • 15 patients (6.3%) had a complete response to SL-DOX.
  • 177 patients (74.4%) had a partial response.
  • 44 patients (18.5%) had stable disease.
  • Neutropenia occurred in 57.1% of patients for whom data were available.

Takeaway

This study tested a special type of medicine called SL-DOX to help people with a serious skin cancer related to AIDS, and it worked well for many patients.

Methodology

Patients were treated biweekly with varying doses of SL-DOX, and tumor response was assessed using AIDS Clinical Trials Group criteria.

Limitations

The study primarily included severely immunocompromised patients, which may limit the generalizability of the results.

Participant Demographics

{"age_mean":39.1,"male_percentage":98.0,"race":{"caucasian_percentage":93.1,"non_caucasian_percentage":6.9},"risk_factors":{"homosexuality_percentage":85.0,"IVDA_percentage":4.0},"CD4_count_median":30.5}

Statistical Information

Confidence Interval

76% to 86%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication